科濟藥業-B(02171.HK):於《Nature Medicine》及2024年ASCO年會上呈列的CT041研究成果更新
格隆匯6月4日丨科濟藥業-B(02171.HK)發佈公吿,CT041(satricabtagene autoleucel,satri-cel,一種靶向Claudin18.2自體CAR-T細胞候選產品)由研究者發起的臨牀試驗CT041- CG4006 (NCT03874897)最終結果於2024年6月3日發表在《Nature Medicine》雜誌上,並於2024年6月3日下午12:30-下午3:30(美國東部夏令時間)在美國臨牀腫瘤學會(“ASCO”)年會上進行口頭報吿。
發表在《Nature Medicine》雜誌上的文章題為“靶向Claudin18.2嵌合抗原受體T細胞治療胃腸道腫瘤:1期臨牀試驗的最終結果”(“Claudin18.2-specific CAR T Cells in gastrointestinal cancers: phase 1 trial final results”)。
發表在2024 ASCO年會上的摘要標題為“靶向Claudin18.2嵌合抗原受體T 細胞用於治療胃腸道腫瘤患者:CT041-CG4006 1 期臨牀試驗最終結果”(“Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Gastrointestinal Cancers: Final Results of CT041-CG4006 Phase 1 Trial”)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.